Tags

Type your tag names separated by a space and hit enter

Long-acting hormonal contraceptives for women.
J Steroid Biochem Mol Biol. 1991; 40(4-6):697-704.JS

Abstract

Following the development and widespread use of oral hormonal contraceptives, it became evident that alternative long-acting delivery systems would be required to improve contraceptive practice in some cultural settings where injectable or subdermal routes of administration are preferred. Nowadays, long-acting contraceptives constitute an important option in family planning services in many parts of the world. Indeed, two long-acting injectable contraceptives containing just a synthetic progestogen (depot-medroxyprogesterone acetate (DMPA) and norethisterone enantate (NET-EN)) have been in clinical practice for more than 20 years. The World Health Organization's (WHO) Special Programme of Research in Human Reproduction, in collaboration with the U.S. National Institute of Child Health and Human Development (NICHD) and universities primarily in developing countries undertook a synthesis programme aimed at producing an improved injectable preparation by developing new derivatives of known steroids. One such compound (levonorgestrel 17-butanoate) is now at the stage of Phase II clinical testing. In addition, the Special Programme has developed and improved once-a-month injectable formulations and assessed their safety and efficacy in different countries worldwide. After large scale clinical testing, at least two progestogen-estrogen combinations have reached the point of introductory trials.

Authors+Show Affiliations

Department of Reproductive Biology, National Institute of Nutrition S. Zubirán, Mexico City, Mexico.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1958567

Citation

Garza-Flores, J, et al. "Long-acting Hormonal Contraceptives for Women." The Journal of Steroid Biochemistry and Molecular Biology, vol. 40, no. 4-6, 1991, pp. 697-704.
Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. J Steroid Biochem Mol Biol. 1991;40(4-6):697-704.
Garza-Flores, J., Hall, P. E., & Perez-Palacios, G. (1991). Long-acting hormonal contraceptives for women. The Journal of Steroid Biochemistry and Molecular Biology, 40(4-6), 697-704.
Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting Hormonal Contraceptives for Women. J Steroid Biochem Mol Biol. 1991;40(4-6):697-704. PubMed PMID: 1958567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-acting hormonal contraceptives for women. AU - Garza-Flores,J, AU - Hall,P E, AU - Perez-Palacios,G, PY - 1991/1/1/pubmed PY - 1991/1/1/medline PY - 1991/1/1/entrez KW - Clinical Research KW - Contraception KW - Contraception Continuation KW - Contraception Research KW - Contraceptive Agents, Estrogen--administraction and dosage KW - Contraceptive Agents, Female--administraction and dosage KW - Contraceptive Agents, Progestin--administraction and dosage KW - Contraceptive Agents--administraction and dosage KW - Contraceptive Implants KW - Contraceptive Methods KW - Contraceptive Mode Of Action KW - Contraceptive Usage KW - Depo-provera--administraction and dosage KW - Estradiol Enanthate--administraction and dosage KW - Family Planning KW - Human Volunteers KW - Iud KW - Iud, Hormone Releasing KW - Levonorgestrel--administraction and dosage KW - Literature Review KW - Medroxyprogesterone Acetate--administraction and dosage KW - Norethindrone Enanthate--administraction and dosage KW - Norethindrone--administraction and dosage KW - Ovulation Suppression KW - Research Methodology KW - Vaginal Rings SP - 697 EP - 704 JF - The Journal of steroid biochemistry and molecular biology JO - J Steroid Biochem Mol Biol VL - 40 IS - 4-6 N2 - Following the development and widespread use of oral hormonal contraceptives, it became evident that alternative long-acting delivery systems would be required to improve contraceptive practice in some cultural settings where injectable or subdermal routes of administration are preferred. Nowadays, long-acting contraceptives constitute an important option in family planning services in many parts of the world. Indeed, two long-acting injectable contraceptives containing just a synthetic progestogen (depot-medroxyprogesterone acetate (DMPA) and norethisterone enantate (NET-EN)) have been in clinical practice for more than 20 years. The World Health Organization's (WHO) Special Programme of Research in Human Reproduction, in collaboration with the U.S. National Institute of Child Health and Human Development (NICHD) and universities primarily in developing countries undertook a synthesis programme aimed at producing an improved injectable preparation by developing new derivatives of known steroids. One such compound (levonorgestrel 17-butanoate) is now at the stage of Phase II clinical testing. In addition, the Special Programme has developed and improved once-a-month injectable formulations and assessed their safety and efficacy in different countries worldwide. After large scale clinical testing, at least two progestogen-estrogen combinations have reached the point of introductory trials. SN - 0960-0760 UR - https://www.unboundmedicine.com/medline/citation/1958567/Long_acting_hormonal_contraceptives_for_women_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0960-0760(91)90293-E DB - PRIME DP - Unbound Medicine ER -